Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients

Transplant International

Volumn 22, Issue 4, 2009, Pages 447-454

  Toki, Daisuke ^a,b   Ishida, Hideki ^b   Horita, Shigeru ^b   Setoguchi, Kiyoshi ^b   Yamaguchi, Yutaka ^c   Tanabe, Kazunari ^b  

^a Tokyo Women's Medical University ^*  (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ABO incompatible renal transplantation; CD20 antigen; Desensitization protocol

Indexed keywords

BASILIXIMAB; CD19 ANTIGEN; CD20 ANTIGEN; CD79A ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG POTENCY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RECIPIENT; SPLEEN CELL; SPLENECTOMY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SPLEEN; SPLENECTOMY;

EID: 61849155125     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00821.x     Document Type: Article

References (21)

1. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002 74 : 1207.
2. Gloor J, DeGoey S, Pineda A, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003 3 : 1017.
3. Sonnenday C, Warren D, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004 4 : 1315.
4. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005 5 : 145.
5. Becker Y, Becker B, Pirsch J, Sollinger H. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004 4 : 996.
6. Lehnhardt A, Mengel M, Pape L, Ehrich J, Offner G, Strehlau J. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab. Am J Transplant 2006 6 : 847.
7. Vieira C, Agarwal A, Book B, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004 77 : 542.
8. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006 6 : 2418.
9. Ramos E, Pollinger H, Stegall M, Gloor J, Dogan A, Grande J. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007 7 : 402.
10. Setoguchi K, Ishida H, Shimmura H, et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant 2008 8 : 86.
11. Ishida H, Miyamoto N, Shirakawa H, et al. Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation - single center analysis. Am J Transplant 2007 7 : 825.
12. Toma H. ABO-incompatible renal transplantation. Urol Clin North Am 1994 21 : 299.
13. Schröder C, Azimzadeh A, Wu G, Price J, Atkinson J, Pierson R. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003 12 : 19.
14. Mason D, Cordell J, Brown M, et al. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood 1995 86 : 1453.
15. Ryan D, Kossover S, Mitchell S, Frantz C, Hennessy L, Cohen H. Subpopulations of common acute lymphoblastic leukemia antigen-positive lymphoid cells in normal bone marrow identified by hematopoietic differentiation antigens. Blood 1986 68 : 417.
16. Dworzak M, Fritsch G, Fröschl G, Printz D, Gadner H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood 1998 92 : 3203.
17. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003 102 : 3514.
18. Cragg M, Bayne M, Illidge T, Valerius T, Johnson P, Glennie M. Apparent modulation of CD20 by rituximab: an alternative explanation. Blood 2004 103 : 3989 author reply 90-1.
19. Mitsuhata N, Fujita R, Ito S, Mannami M, Keimei K. Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation. Transplantation 2005 80 : 1355.
20. Mitsuhata N, Fujita R, Ito S, Mannami M, Kojima K. Is administration of rituximab at 375 mg/m without splenectomy appropriate for ABO-incompatible renal transplant? Am J Transplant 2005 5 : 3019. author reply 20.
21. Segev D, Simpkins C, Warren D, et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005 5 : 2570.